The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp.

The activity of grepafloxacin, a new orally active fluoroquinolone, was compared with the activities of ofloxacin, clarithromycin and doxycycline against Chlamydia pneumoniae, Chlamydia trachomatis, Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum, and with the activities of ofloxacin, clarithromycin and rifampicin against Legionella spp. Grepafloxacin (MIC range 0.06-0.12 mg/L) was some 8-16 times more active than ofloxacin against the chlamydiae, showing activity similar to that of doxycycline, and equal or two-to four-fold less active than clarithromycin. Grepafloxacin was four-fold more active than ofloxacin against M. pneumoniae (MIG 0.06-0.5 mg/L) and U. urealyticum (MIG 0.12-1.0 mg/L), but 16 times more active against M. hominis (MIG 0.015-0.05 mg/L). Grepafloxacin was highly active against Legionella spp. (MIG 0.008-0.03 mg/L), showing equivalent activity to ofloxacin, clarithromycin and rifampicin.